Press Releases

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

FOURTH QUARTER February 1, 2018 – April 30, 2018
  • Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous year
  • Operating loss was T...

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer.

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The cur...

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned, US-based...

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago....

Notification from Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (publ) hereby notify that the Company, Arwidsro Investment and MGC Capital have agreed to extend the payment of the loan, which was communicated January 2nd  until...

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that EMA has given 60 days response time instead of 30 days as previously communicated and requested by the company. Oasmia will respond to the...

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that the Company has submitted a Form F-3 to SEC which is a required document in case the Company would need to do a financial transaction in the ...

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification regarding the issuance of the agenda for EMA’s CHMP meeting April 23 – 26. Instead of the announced oral explanation, Oasmia will respond to o...

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an in...